A Phase 3 interventional study of Bel-sar and Suprachoroidal Microinjector in Choroidal Melanoma, Indeterminate Lesions and Uveal Melanoma, sponsored by Aura Biosciences. Active, not recruiting at 53 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Aura Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 191 studies in Uveal Melanoma with a site in United States — 26 open to participants now, 51 under way, 7 of them phase 3. Uveal Melanoma · United States.
Among the 191 studies in Uveal Melanoma with a site in United States, this one is the 25th largest by enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2023, is one of 10 in phase 3, reaches primary completion later than 29 of the 50 other live ones, and was the 169th registered.
281 studies on the registry are indexed under Uveal Melanoma; 50 are open to participants now.
Browse Uveal Melanoma studies →26 of the 191 studies in Uveal Melanoma with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
IDEAYA Biosciences · Sites in United States, Australia, Canada and 3 more countries
Ages 18+
VM Discovery, Inc. · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18+
IDEAYA Biosciences · Sites in United States, Australia, Austria and 18 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Uveal Melanoma studies recruiting now, 36 (84%) set no upper age limit and 4 (9%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
191 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 102 · Phase 3 12 · Phase 4 1
First in 1996; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 108 is above the median of 37 across 222 interventional studies indexed under Uveal Melanoma.
Median enrollment 36 across the 163 interventional studies, 79 across the 18 observational. Of the 130 that completed or were terminated, 58 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 191 have an industry lead sponsor. The 10 most frequent:
Aura Biosciences is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Aura Biosciences has 7 studies filed under Uveal Melanoma — fewer than ten, so there is no comparison to draw.
16 of the studies in Uveal Melanoma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05987332Phase 3IDEAYA BiosciencesIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | 2027-01-15 |
| NCT06007690Phase 3Aura BiosciencesA Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | 2027-11-15 |
| NCT01587352National Cancer Institute (NCI)Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | 2026-12-31 |
| NCT03947385IDEAYA BiosciencesStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | 2027-01-29 |
| NCT04728633Thomas Jefferson UniversityTransarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases | 2027-01-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 191 studies in Uveal Melanoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
This is a randomized, sham-controlled, subject-, assessor-, and Sponsor- masked trial to establish the safety and efficacy of bel-sar treatment via suprachoroidal (SC) administration in subjects with primary IL/CM. Bel-sar treatment incorporates administration of bel-sar drug product using a suprachoroidal space (SCS) microinjector and activation of bel-sar by a laser photoactivation device.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
High dose of bel-sar + laser application
Drug: Bel-sar · Device: Suprachoroidal Microinjector · Device: Infrared Laser
Low dose of bel-sar + laser application
Drug: Bel-sar · Device: Suprachoroidal Microinjector · Device: Infrared Laser
Sham injection + sham laser
Device: Sham Infrared Laser · Device: Sham Microinjector
Bel-sar via suprachoroidal administration followed by laser application.
Also known as: AU-011
Suprachoroidal injection device
Also known as: SCS Microinjector
Laser application
Sham laser application
Sham injection device
Time to reach tumor progression
Tumor Progression
Time frame: 65 weeks
Time to composite endpoint
Tumor progression or visual acuity failure
Time frame: 65 weeks
Plan to share: No
Started Dec 2023 (actual). Primary completion is estimated for Nov 2027, 47 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belzupacap sarotalocan
Aura Biosciences